Mesoblast (ASX:MSB) YoY EBITDA Growth : 100.00% (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Mesoblast's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was 100.00%.

Mesoblast's EBITDA per Share for the three months ended in Jun. 2024 was A$0.00.

Mesoblast YoY EBITDA Growth Historical Data

The historical data trend for Mesoblast's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast YoY EBITDA Growth Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

YoY EBITDA Growth

Get a 7-Day Free Trial

23.18

2.79

16.09

23.29

14.29

Mesoblast Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EBITDA Growth	Get a 7-Day Free Trial															100.00	100.00	100.00	100.00	-

Mesoblast YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Mesoblast's YoY EBITDA Growth for the fiscal year that ended in Jun. 2024 is calculated as:

	YoY EBITDA Growth (A: Jun. 2024 )
=	(EBITDA per Share (A: Jun. 2024 )	-	EBITDA per Share (A: Jun. 2023 ))	/	\| EBITDA per Share (A: Jun. 2023 ) \|
=	(-0.096	-	-0.112)	/	\| -0.112 \|
=	14.29 %

Mesoblast's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

	YoY EBITDA Growth (Q: Jun. 2024 )
=	(EBITDA per Share (Q: Jun. 2024 )	-	EBITDA per Share (Q: Jun. 2023 ))	/	\| EBITDA per Share (Q: Jun. 2023 )) \|
=	(0	-	-0.031)	/	\| -0.031 \|
=	100.00 %

Mesoblast YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Mesoblast's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany LWB:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.